(Q44606439)

4 December 2017

Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants (English)

1 reference

4 December 2017

1 reference

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2003-08-2644

17 March 2024

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2003-08-2644

17 March 2024

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2003-08-2644

17 March 2024

5

Michael Boeckh

1 reference

4 December 2017

9

Lawrence Corey

1 reference

4 December 2017

3

Wendy Leisenring

1 reference

4 December 2017

7

W Garrett Nichols

1 reference

4 December 2017

1

Kieren A Marr

1 reference

4 December 2017

2

Fulvio Crippa

1 reference

4 December 2017

6

S Arunmozhi Balajee

1 reference

4 December 2017

Maggie Hoyle

4

1 reference

4 December 2017

Benjamin Musher

8

1 reference

4 December 2017

language of work or name

English

0 references

publication date

2 October 2003

1 reference

full work available at URL

4 December 2017

published in

Blood

1 reference

4 December 2017

103

1 reference

4 December 2017

4

1 reference

4 December 2017

1527-1533

1 reference

A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation

4 December 2017

1

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2003-08-2644

Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation--a prospective, randomized, double-blind study.

17 March 2024

2

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2003-08-2644

Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors.

17 March 2024

4

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2003-08-2644

Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients

17 March 2024

5

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2003-08-2644

Late onset of invasive aspergillus infection in bone marrow transplant patients at a university hospital

17 March 2024

6

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2003-08-2644

Incidence and risk factors for invasive fungal infections in allogeneic BMT recipients

17 March 2024

7

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2003-08-2644

Epidemiology ofAspergillusInfections in a Large Cohort of Patients Undergoing Bone Marrow Transplantation

17 March 2024

8

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2003-08-2644

A randomized controlled trial of itraconazole versus fluconazole for the prevention of fungal infections in patients with haematological malignancies. U.K. Multicentre Antifungal Prophylaxis Study Group

17 March 2024

9

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2003-08-2644

Itraconazole oral solution for primary prophylaxis of fungal infections in patients with hematological malignancy and profound neutropenia: a randomized, double-blind, double-placebo, multicenter trial comparing itraconazole and amphotericin B.

17 March 2024

10

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2003-08-2644

Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy. A randomized, controlle

17 March 2024

11

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2003-08-2644

Itraconazole oral solution as prophylaxis for fungal infections in neutropenic patients with hematologic malignancies: a randomized, placebo-controlled, double-blind, multicenter trial. GIMEMA Infection Program. Gruppo Italiano Malattie Ematologiche

17 March 2024

12

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2003-08-2644

Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus.

17 March 2024

13

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2003-08-2644

Screening for circulating galactomannan as a noninvasive diagnostic tool for invasive aspergillosis in prolonged neutropenic patients and stem cell transplantation recipients: a prospective validation.

17 March 2024

14

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2003-08-2644

Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and candida infections. Subcommittee on Antifungal Susceptibility Te

17 March 2024

16

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2003-08-2644

Correlation between in-vitro susceptibility testing to itraconazole and in-vivo outcome of Aspergillus fumigatus infection

17 March 2024

17

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2003-08-2644

Candidemia in allogeneic blood and marrow transplant recipients: evolution of risk factors after the adoption of prophylactic fluconazole.

17 March 2024

18

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2003-08-2644

Cyclophosphamide metabolism, liver toxicity, and mortality following hematopoietic stem cell transplantation

17 March 2024

22

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2003-08-2644

Cyclophosphamide metabolism is affected by azole antifungals

17 March 2024

23

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2003-08-2644

Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. A multicenter, randomized trial

17 March 2024

24

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2003-08-2644

Survival and prognostic factors of invasive aspergillosis after allogeneic bone marrow transplantation

17 March 2024

26

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2003-08-2644

Multiple dose pharmacokinetics of an oral solution of itraconazole in autologous bone marrow transplant recipients

17 March 2024

27

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2003-08-2644

Multiple dose pharmacokinetics of an oral solution of itraconazole in patients receiving chemotherapy for acute myeloid leukaemia.

17 March 2024

28

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2003-08-2644

Breakthrough invasive fungal infections in neutropenic patients after prophylaxis with itraconazole

17 March 2024

29

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2003-08-2644

Effects of the antifungal agents on oxidative drug metabolism: clinical relevance

17 March 2024

30

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2003-08-2644

Problems in dealing with missing data and informative censoring in clinical trials

17 March 2024

31

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2003-08-2644

17 March 2024

Identifiers

1 reference

4 December 2017

1 reference